Simvastatin nanoparticles attenuated intestinal ischemia/reperfusion injury by downregulating BMP4/COX-2 pathway in rats

Fei Tong1
Bo Dong1
Rongkui Chai1
Ke Tong2,3
Yini Wang4
Shipiao Chen1
Xinmei Zhou1
Daojun Liu5

1Department of Pathology and Pathophysiology, Provincial Key Discipline of Pharmacology, Jiaxing University Medical College, Jiaxing, Zhejiang, 2College of Life Science and Engineering, State Defense Key Laboratory of Fundamental Science on Nuclear Wastes and Environment, Southwest University of Science and Technology, Mianyang, Sichuan, 3Department of Nursing, Zhejiang Rongjun Hospital, The Third People’s Hospital of Jiaxing, Jiaxing, Zhejiang, 4Department of Pharmacochemistry, Shantou University Medical College, Shantou, Guangdong, People’s Republic of China

Abstract: The purpose of the research was to explore the therapeutic action of simvastatin-loaded poly(ethylene glycol)-b-poly(gamma-benzyl L-glutamate) (PEG-b-PBLG50) on intestinal ischemia/reperfusion injury (II/RI) through downregulating bone morphogenetic protein 4 (BMP4)/cyclooxygenase-2 (COX-2) pathway as compared to free simvastatin (Sim). Sprague Dawley rats were preconditioned with 20 mg/kg Sim or simvastatin/PEG-b-PBLG50 (Sim/P) compounds, and then subjected to 45 min of ischemia and 1 h of reperfusion. The blood and small intestines were collected, serum levels of interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-α, and nitric oxide (NO) were checked, and the dry/wet intestine ratios, superoxide dismutase activity, myeloperoxidase content, reactive oxygen species, endothelial nitric oxide synthase, protein 47 kDa phagocyte oxidase (p47phox), BMP4, COX-2, and p38 mitogen-activated protein kinase (p38MAPK) expressions were measured in intestinal tissues. Both Sim and Sim/P pretreatment reduced intestinal oxidative damnification, restricted inflammatory harm, and downregulated the BMP4 and COX-2 expressions as compared to II/RI groups, while Sim/P remarkably improved this effect.

Keywords: PEG-b-PBLG50, II/RI, simvastatin, BMP4, COX-2

Introduction

Intestinal ischemia/reperfusion injury (II/RI) is a major pathophysiological phenomenon and a potentially life-threatening problem in clinical medicine.1,2 The mortality rates from II/RI are very high and reach more than 60% and it often requires clinical operation to cut off the necrotic intestinal segment.3,4 It causes the tissue injury through inadequate blood and oxygen supply relative to cellular energy stores exhaustion, tissue metabolic disorder, and toxic metabolites accumulation in intestinal ischemia phase and leads to reactive oxygen species (ROS), inflammatory factors, calcium overload, and so on, mediating the further damage of intestine in reperfusion phase.5 It is well known that oxygen supply reestablishment results in ROS production, causing lipid oxidation reaction in cell membranes,6 and blood supply reestablishment leads to production of a lot of inflammatory factors to aggravate tissue injury and intestinal barrier dysfunction, and toxic metabolite products enter the systemic blood circulation and threaten life.7

ROS is engendered on intestinal ischemia/reperfusion (I/R), and is one of the major reasons of intestinal damage.8 Previous studies have showed that nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is the key enzyme that is involved in ROS production.9 NADPH oxidase is composed of at least five protein components
and three cytosolic components (including p47phox).

P47phox is the subunit mainly responsible for transporting the cytosolic complex from the cytosol to the membrane in oxidative activation and impels ROS production. Many exogenous antioxidants (including superoxide dismutase [SOD]) aimed to reduce ROS damage have been studied in the treatment of I/R-induced intestinal injury. More and more evidence has demonstrated that stimulation of endogenous antioxidant systems may be an important tactic for achieving intestinal protection on I/R injury.

The disorder of proinflammatory and anti-inflammatory factors boosts II/RI. Proinflammatory factors including interleukin-6 (IL-6) and tumor necrosis factor (TNF-α) generated largely, and anti-inflammatory factors including interleukin-4 (IL-4) and interleukin-10 (IL-10) engendering insufficiently via damaged intestines and blood have been involved as the chief contributor of II/RI.

Bone morphogenetic protein 4 (BMP4) is one of the BMP families (including BMP2-BMP9). Previous studies have affirmed that BMP4 has a role with BMP receptors involving type I and type II and then adjusts physiopathologic process of bodies. Some documents have shown that BMP4 exacerbates exageratin cardiac I/R injury. In addition, BMP4 is a proinflammatory gene that induces endothelium dysfunction, mediating abnormal expression of endothelial nitric oxide synthase (eNOS) and leads to impairment of vascular relaxation, and that activates NADPH oxidase to induce ROS production and then improves the expression of cyclooxygenase-2 (COX-2) through p38 mitogen-activated protein kinase (p38MAPK). COX-2 promotes vasopermeability and aggravates tissues’ damage.

Many documents have attested that simvastatin (Sim) can protect the small intestine against (I/R) damnification. In the present study, we try to explore the protective effect of Sim on II/RI. As is well known, the in vivo solubility of Sim is very low and circulation time is very short. Here, a poly(ethylene glycol)-b-poly(gamma-benzyl-L-glutamate) (PEG-b-PBLG) block multipolymer (framework depicted in Figure 1) as a latent Sim nanoparticle is reported. The block multipolymer is synthesized through the ring-opening polymerization of BLG-N-carboxyanhydride (NCA) with PEG-NH₂ as the macrominitiator. The P and Sim integrate into a compound through hydrophobic functions. The encapsulated Sim shows stable release, which can promote the research on the protective action of Sim. Sim loading and in vitro release are confirmed. In vivo research is conducted through the hypodermic injection of the Sim/P compound to II/RI in rats, followed by the determination of serum IL-4, IL-6, IL-10, TNF-α, and nitric oxide (NO), measurements of SOD activity and methane dicarboxylic aldehyde (MDA) level in small intestinal tissues, and finally the ROS, eNOS, protein 47 kDa phagocyte oxidase (p47phox), BMP4, COX-2, and p38MAPK expressions in small intestinal tissues.

Materials and methods

Material

PEG-NH₂ (molecular weight, 5 kDa), dimethyl formamide (DMF), and BLG were bought from Aladdin (Shanghai, China); regenerative fiber dialysis bag (molecular weight cut off [MWCO], 3.5 kDa, 7 kDa) was bought from Union Cardiobide Company (Danbury, CT, USA); simvastatin was bought from Shangyu Hangzhou Jing Xin Pharmaceutical Co., Ltd.; Hela cells were bought from Shanghai Forte Cheng Biological Technology Co., Ltd.; other reagents were bought from Sigma.

Methods

Synthesis of PEG-b-PBLG

PEG-b-PBLG₅₀ was synthesized by following way: The ring-opening polymerization of BLG-N-carboxyanhydride with PEG-NH₂ as the macronitiator obtained PEG-b-PBLG, as described in Figure 2. BLG-NCA was synthesized and characterized by a previously published method. The right amount of PEG-NH₂ in 10 mL of DMF was mixed with a quantity of BLG-NCA/DMF fluid (0.1 g/mL) by vacuumization and nitrogen protection. The corresponsive compounds were stirred at 40°C for 3 days and dialyzed for 3 days using dialysis tubing (MWCO, 7 kDa). The PEG-b-PBLG polymers were gained by freeze drying, the degree of polymerization of PBLG was 50, and they were characterized by ¹H-nuclear
Attenuation of intestinal ischemia/reperfusion injury by simvastatin NPs

magnetic resonance, gel permeation chromatogram, and Fourier transform infrared spectroscopy.

Cytotoxicity evaluation of PEG-b-PBLG_{50}
The detailed method for the cytotoxicity evaluation of block copolymer PEG-b-PBLG_{50} is referred to the technology and method specified in our previous article.29

Encapsulation of simvastatin through PEG-b-PBLG_{50}
To assess the loading of simvastatin by PEG-b-PBLG_{50}, a certain amount of simvastatin (5 mg/mL) in phosphate buffered solution (PBS) (pH = 7.2, 0.01 mmol/L; including 2% dimethyl sulfoxide) was mixed with PEG-b-PBLG_{50} in a PB solution. And then the mixed solutions were transferred to a dialysis bag (MWCO, 7 kDa) and dialyzed. When the sunk polymer in the test was wholly removed, the polymer-loaded simvastatin was measured through high-performance liquid chromatography (HPLC) and transmission electron microscopy (TEM).

In vitro release of simvastatin from PEG-b-PBLG_{50}
Simvastatin releases from the PEG-b-PBLG_{50} were detected by dialysis (MWCO, 7 kDa) at room temperature with 5 mL of simvastatin/PEG-b-PBLG_{50} compound against 60 mL of 0.02 mol/L PB (pH 7.4). At 0.02-, 0.04-, 0.08-, 0.17-, 0.33-, 0.42-, 0.5-, 0.67-, 0.75-, 1-, 1.5-, 1.67-, 1.75-, 2-, 3-, and 4-day time interval, a certain amount of release mediums were retrieved and supplemented with a proper amount of fresh release mediums. The quantity of released simvastatin remaining in the dialysis bag was measured through HPLC. The free simvastatin releases in the absence of polymeric compound were also executed as a control.

Blood simvastatin concentration evaluation
The Sprague Dawley (SD) rats were administrated a dose of 20 mg/kg simvastatin (Sim) or simvastatin/PEG-b-PBLG_{50} (Sim/P) by abdominal subcutaneous injection. Blood (0.2 mL) was extracted to put into heparinized tubes at specified time intervals. Blood was separated immediately by centrifugation (12,000 \times g for 15 min at 4°C) and stored under −80°C for the following analyses. The concentration of Sim and Sim/P in rat blood was measured by liquid chromatography tandem mass spectrometry following the previous methods.30

The distribution of simvastatin/polymer compound in SD rats
The SD rats were administrated a dose of 20 mg/kg Sim or Sim/P by abdominal subcutaneous injection. The different tis-
sues were extracted and put into test tubes, where the miscible liquids containing 0.2 mL 60% perchloric acid and 0.2 mL 30% hydrogen peroxide were added. The samples were put into an 80°C water bath for 40–60 min and then the color of the samples became faint yellow. 0.2 mL of the tissues liquids were extracted to add 1 mL of scintillation solution and 3 mL of absolute ethyl alcohol, then the radioactivity of different tissues were checked by TRI-CARB2900 TR liquid scintillation counter (PACKARB) following previous methods.31

Animal and surgical procedures of I/R
SD rats (180–220 g) wereaccommodated by the Animal Research Center of Jiaxing University Medical College, Jiaxing, People’s Republic of China. All the procedures and care administered to the animals had been approved by the Institutional Ethics Committee of Jiaxing University Medical College. The investigation conformed to the guide for the care and use of laboratory animals published by the US National Institutes of Health (NIH Publication updated in 2011). In the research, 40 SD rats were assigned to four groups (each group including 10 rats): 1) Sham group; 2) I/R group; SD rats were anesthetized with 1% pentobarbital sodium (50 mg/kg) through intraperitoneal injection. The abdomina were opened and the arteriae mesenterica superior were separated to be clamped for 45 min by a small vessel clip, followed by 1 h of reperfusion; 3) simvastatin (Sim) group: Sim was administrated once a day (20 mg/kg) through abdominal subcutaneous injection, for 8 days prior to the I/R procedures; 4) simvastatin/PEG-b-PBLG₄₀ (Sim/P) group: Sim/P was administrated once every 4 days (20 mg/kg) through abdominal subcutaneous injection, for 8 days prior to the I/R procedures. The blood was collected from the abdominal aorta and centrifuged under 3,600× g for 20 min to gain the liquid supernatant. The SOD activity and MDA level were checked through xanthine oxidase and thiobarbituric acid method. The absorbances were checked at 350 nm. The content of NO₂⁻/NO₃⁻ is shown in “µmol” of NO₂⁻/NO₃⁻/L serum.

Measurement of serum IL-4, IL-6, IL-10, and TNF-α content
The method was depicted mainly through previous reports. The IL-4, IL-6, IL-10, and TNF-α contents were measured by double anti-sandwich ABC-ELISA method. The absorbances were checked at 450 and 492 nm, respectively. The levels of IL-4, IL-6, IL-10, and TNF-α were expressed in “ng” of IL-4, IL-6, IL-10, and TNF-α/L serum.

Evaluation of ROS
Previous methods have been referred to here. After 1 h of reperfusion, SD rats were anesthetized with 1% pentobarbital sodium (50 mg/kg), and CM-H₂DCFDA (100 µg) was injected into the intestinal circulation. After CM-H₂DCFDA injection, the small intestine was harvested for 45 min and dipped in 4% paraformaldehyde for about 24 h. After treatment with 20% sucrose for about 12 h, the small intestine was immediately frozen in liquid nitrogen. Cryostat sections were cut at −20°C and the sections were placed on Star-Frost adhesive slides and air-dried for about 3 min. Parts were washed in PBS and stained with DAPI for fluorescence microscopy analysis in ROS qualitative evaluation. ROS quantitative evaluation in isolated mitochondria was performed using the amplex red H₂O₂/peroxidase assay kit using a spectrofluorometer and emission wavelengths of 544 and 590 nm, respectively.

Western blot analysis
Previous methods have been referred to here. Briefly, small intestinal tissues were homogenized in protein lysate buffer. The homogenate was resolved on polyacrylamide sodium dodecyl sulfate gels, and electrophoretically transferred to polyvinylidene difluoride membranes. The membrane was blocked with 3% bovine serum albumin, and incubated with primary antibodies (Abs) against active eNOS, p47phox, p38MAPK, BMP4, COX-2, and subsequently with alkaline phosphatase-conjugated secondary Abs. It was developed via 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium. Blot was stained through anti-β-actin Ab, and the content of protein was normalized with respect to β-actin and density.
Immunohistochemical assessment

Previous methods have been referred to here. Sections with a thickness of 5 μm were obtained from the small intestine parts and mounted on poly-L-lysine-coated slides. The parts were immersed in 0.3% H₂O₂ for 20 min and washed with PBS. The parts were then incubated in rabbit anti-COX-2, anti-BMP4, and anti-p38MAPK polyclonal antiserum (Abcam, UK) for 1 h (1:100 dilution). After the primary incubation and three rinses in PBS, parts were incubated in biotinylated goat anti-rabbit IgG (Invitrogen, CA, USA) for 15 min (1:2,000 dilution). Following the incubation in substrate chromagen solution for 15 min, all parts were washed in PBS and distilled water, mounted in glycerol, and checked later under the microscope. The small intestinal parts stained positively for COX-2, BMP4, and p38MAPK were evaluated and compared among groups.

Statistical analysis

All experiments were repeated in triplicate. All the data were depicted as mean values ± standard deviation. An analysis of variance test and a Student’s t-test usually assessed statistical significance. A value of <0.01 (P<0.01) was regarded as statistically significant.

Results

Synthesis and characterization of PEG-b-PBLG₅₀

The PEG-b-PBLG was made up of a PEG block and aPBLG (Figure 1). In the current research, the molecular weight of PEG block was 5 kDa, and the degree of polymerization of the PBLG was 50. The synthesis was accomplished in a step order as depicted in Figure 2A. The ³H NMR spectra of PEG-b-PBLG₅₀ is depicted in Figure 2B, and the characteristic proton peaks of both PEG and PBLG block were in existence, corroborating that the synthesis proceeded in a controlled way and was successful. The gel permeation chromatograms (GPCs) of PEG-b-PBLG are depicted in Figure 3 and the GPCs showed a sharp unimodal GPC peak, and the molecular weight of the termination product PEG-b-PBLG₅₀

Figure 3 Characterization of PEG-b-PBLG₅₀ and simvastatin/PEG-b-PBLG₅₀ complexes.

Notes: (A) TEM image of simvastatin/PEG-b-PBLG₅₀ complexes; (B) Cellular viability of EC9706 cells cultured with different concentrations of PEG-b-PBLG₅₀ and results expressed as mean ± standard deviation; (C) Cumulative releasing profile of simvastatin from simvastatin/PEG-b-PBLG₅₀ complexes and results expressed as mean ± standard deviation. (D) Blood simvastatin concentration of simvastatin and simvastatin/PEG-b-PBLG₅₀ complexes in rats and results expressed as mean ± standard deviation.

Abbreviations: PEG-b-PBLG₅₀ poly(ethylene glycol)-b-poly(gamma-benzyl L-glutamate); TEM, transmission electron microscopy.
gained from the GPC detection is listed in Table 1. The FT-IR of PEG-b-PBLG<sub>50</sub> is depicted in Figure 3D and the FT-IR showed that the absorption peaks at 1,734 and 1,167 cm<sup>-1</sup> were the ester linkage of PEG-b-PBLG<sub>50</sub>, and the characteristic peaks at 1,652 and 1,547 cm<sup>-1</sup> were acid amides I and II, affirming that the synthesis proceeded successfully.

### Cellular viability evaluation

The evaluation of cell toxicity from PEG-b-PBLG<sub>50</sub> on EC9706 cells was checked in 24-h culturing and the result is revealed in Figure 3B. The PEG-b-PBLG<sub>50</sub> showed low cell toxicity even below a concentration as high as 300 μg/mL.

### Loading capacity of simvastatin in PEG-b-PBLG<sub>50</sub>

Simvastatin could be efficiently loaded through PEG-b-PBLG<sub>50</sub> at physiological pH by the hydrophobic interaction. Simvastatin was added to PEG-b-PBLG<sub>50</sub> (mass ratio, 1:5) and dialyzed (MWCO, 7 kDa) against PB solution (pH 7.4, 0.01 mmol/L). The dialysis of free simvastatin as a control was also conducted at the same condition in a PB solution. To decide the load of simvastatin in PEG-b-PBLG<sub>50</sub>, the quantity of simvastatin was checked by HPLC in the dialysate and deducted from the total quantity of added simvastatin. The load of simvastatin was 41.8% by calculating, expressed as the mass ratio of loaded simvastatin to the polymeric compound host (Table 1).

### Characterization evaluation of simvastatin/polymer compound

The simvastatin/polymer compound was measured by TEM and the image is revealed in Figure 3A. The simvastatin/polymer compound showed an orbicular structure and the diameter was 73 nm (Table 1).

### In vitro release of simvastatin from PEG-b-PBLG<sub>50</sub>

The simvastatin release from PEG-b-PBLG<sub>50</sub> was measured by dialysis (MWCO, 7 kDa) under room temperature, with 5 mL of simvastatin/PEG-b-PBLG<sub>50</sub> against a PB solution of 0.02 mol/L (pH of 7.4). The release curve of simvastatin/PEG-b-PBLG<sub>50</sub> is depicted in Figure 3C. After 2 h, ~48.94% of the simvastatin was released from simvastatin/PEG-b-PBLG<sub>50</sub>, manifesting the beginning of a burst release of simvastatin. Approximately 67.72% of the simvastatin was released after 2 days and ~97% after 4 days, manifesting biphase release profile from simvastatin/PEG-b-PBLG<sub>50</sub>.

### Plasma simvastatin concentration evaluation

It is shown in Figure 3D. The concentration of simvastatin in the plasma of SD rats following a single subcutaneous injection in Sim group at a dose of 20 mg/kg rapidly reached C<sub>max</sub> of 163.56 ng/mL at a T<sub>max</sub> of 2 h, and declined to baseline values within 10 h of administration. The plasma concentration of SD rats following a single subcutaneous injection in Sim/P group at a dose of 20 mg/kg reached C<sub>max</sub> of 41.25 ng/mL at a T<sub>max</sub> of 2 h, and declined to baseline values within 4 days of administration. These results showed that the release of simvastatin from Sim/P group was substantially sustained compared to Sim group.

### In vivo distribution evaluation of simvastatin/PEG-b-PBLG<sub>50</sub> compound

It is depicted in Figure 4. The disintegrations per minute (DPM) of spleen was maximum and then was kidney and heart. However, the DPM of intestine, lung, and liver was minimum. This showed that a part of simvastatin from simvastatin/PEG-b-PBLG<sub>50</sub> compound was swallowed by the phagocyte of spleen, but was not swallowed by the phagocyte of liver, then a part of simvastatin from simvastatin/PEG-b-PBLG<sub>50</sub> compound accumulated in the kidney, heart,
in I/R group rats was greater than that in the Sham group ($P<0.01$). IL-10 content in serum reached $14.65 \pm 1.23$ ng in Sham group, whereas IL-10 content in serum in I/R group reached $47.53 \pm 2.21$ ng. Administration of simvastatin increased IL-6 level ($60.03 \pm 2.76$ ng) in serum, compared with IL-10 content in serum in the I/R group rats ($P<0.01$).

Administration of simvastatin/PEG-$b$-PBLG$_{50}$ remarkably increased IL-10 content ($78.85 \pm 0.01$ ng), which was remarkably greater than that in the I/R group ($P<0.01$); TNF-α content in serum in I/R group rats was greater than that in the Sham group ($P<0.01$). TNF-α content in serum reached $16.74 \pm 1.32$ ng in Sham group, whereas TNF-α content in serum in I/R group reached $89.23 \pm 2.88$ ng. Administration of simvastatin decreased TNF-α content ($70.66 \pm 1.78$ ng) in serum, compared with TNF-α content in serum in I/R group rats ($P<0.01$). Administration of simvastatin/PEG-$b$-PBLG$_{50}$ remarkably decreased TNF-α content ($54.15 \pm 1.36$ ng), which was remarkably lower than that in I/R group ($P<0.01$).

**Measurement of NO$_2^-$/NO$_3^-$ content and dry/wet intestine ratios**

As shown in Figure 5D and E, NO$_2^-$/NO$_3^-$ content in serum in I/R group rats was lower than that in the Sham group ($P<0.01$). NO$_2^-$/NO$_3^-$ content in serum reached $24.27 \pm 0.08$ μmol in Sham group, whereas NO$_2^-$/NO$_3^-$ content in serum in I/R group reached $7.8 \pm 1.11$ μmol. Administration of simvastatin increased NO$_2^-$/NO$_3^-$ content ($9.12 \pm 0.87$ μmol) in serum, compared with NO$_2^-$/NO$_3^-$ content in serum in I/R group rats ($P<0.01$). Administration of simvastatin/PEG-$b$-PBLG$_{50}$ remarkably increased NO$_2^-$/NO$_3^-$ content ($12.3 \pm 0.65$ μmol), which was remarkably greater than that in the I/R group ($P<0.01$); the dry/wet (D/W) intestine ratios in I/R groups rats were lower than those in Sham group ($P<0.01$). The D/W intestine ratios reached $3.08 \pm 0.06$ in Sham group, whereas the D/W intestine ratios in I/R groups reached $6.25 \pm 0.09$. Administration of simvastatin increased the D/W intestine ratios ($5.17 \pm 0.08$) compared with the D/W intestine ratios in I/R group rats ($P<0.01$), whereas administration of simvastatin/PEG-$b$-PBLG$_{50}$ remarkably increased the D/W intestine ratios ($4.46 \pm 0.10$), which were remarkably higher than those in I/R group ($P<0.01$).

**ROS analysis**

Fluorescence microscopy images of intestine parts are shown in Figure 6. CM-H$_2$DCFDA-positive cells were absent in intestinal tissue parts from Sham group. I/R group augmented mitochondrial ROS production, as affirmed through significant epithelial cell staining (CM-H2DCFDA fluorescence) of
Figure 5 (A) SOD activity; (B) MDA level; (C) Level of IL-4, IL-6, IL-10, and TNF-α; (D) D/W intestine ratios; (E) Level of serum NO$_2^-$/NO$_3^-$.  
**Notes:** The intestinal tissues and serum of Sham, I/R, Sim, and Sim/P group rats were collected 1 h after reperfusion and the level of SOD, MDA, IL-4, IL-6, IL-10, TNF-α, D/W intestine ratios, and NO$_2^-$/NO$_3^-$ measured. Results are expressed as mean ± standard deviation. (A) A significant decrease from Sham group is denoted by *P < 0.01, an increase from I/R group is denoted by **P < 0.01, and a significant increase from I/R group is denoted by ***P < 0.01. (B) A significant increase from Sham group is denoted by *P < 0.01, a decrease from I/R group is denoted by **P < 0.01, and a significant decrease from I/R group is denoted by ***P < 0.01. (C) A significant increase from Sham group is denoted by *P < 0.01, an increase from I/R group is denoted by **P < 0.01, and a significant increase from I/R group is denoted by ***P < 0.01 (IL-4 and IL-10); a significant increase from Sham group is denoted by *P < 0.01, a decrease from I/R group is denoted by **P < 0.01, and a significant decrease from I/R group is denoted by ***P < 0.01 (IL-6 and TNF-α). (D) A significant increase from Sham group is denoted by *P < 0.01, a decrease from I/R group is denoted by **P < 0.01, and a significant decrease from I/R group is denoted by ***P < 0.01 (IL-6 and TNF-α). (E) A significant decrease from Sham group is denoted by *P < 0.01, an increase from I/R group is denoted by **P < 0.01, and a significant increase from I/R group is denoted by ***P < 0.01.  
**Abbreviations:** D/W, dry/wet; I/R, ischemia/reperfusion; IL-10, interleukin-10; MDA, methane dicarboxylic aldehyde; SOD, superoxide dismutase; TNF-α, tumor necrosis factor-α; Sim, simvastatin; Sim/P, simvastatin/Peg-b-PBLG$_{50}$.
intestine tissue parts. Sim/P group significantly reduced ROS production, compared with production of ROS in I/R group.

Western blot evaluation
eNOS, p47phox, p38MAPK, BMP4, and COX-2 expressions in intestinal tissues were checked by Western blot following the previously published method.21,38–40 The qualitative and quantitative outcomes are evaluated in Figure 7. The eNOS expressions in intestinal tissue in I/R group were greater than those in Sham group (P < 0.01). Administration of simvastatin upregulated the eNOS expressions in intestinal tissue, compared with eNOS expressions by I/R group (P < 0.01). Administration of simvastatin/PEG-b-PBLG50 remarkably upregulated eNOS expressions, compared with those in I/R group (P < 0.01).

The p47phox, p38MAPK, BMP4, and COX-2 expressions in intestinal tissue in I/R group were greater than those in Sham group (P < 0.01). Administration of simvastatin downregulated p47phox, p38MAPK, BMP4, and COX-2 expressions in intestinal tissue, compared with p47phox, p38MAPK, BMP4, and COX-2 expressions in I/R groups (P < 0.01). Administration of simvastatin/PEG-b-PBLG50 remarkably downregulated p47phox, p38MAPK, BMP4, and COX-2 expressions, compared with those in I/R group (P < 0.01).

Immunohistochemical analysis
As shown in Figure 8, expressions of COX-2, BMP4, and p38MAPK in intestinal tissues that were induced by I/R are greater than those in Sham group. Administration of simvastatin downregulated COX-2, BMP4, and p38MAPK expressions in intestinal tissue, compared with COX-2, BMP4, and p38MAPK expressions in intestinal tissue by induced I/R group, whereas administration of simvastatin/PEG-b-PBLG50 downregulated COX-2, BMP4, and p38MAPK expressions, which were remarkably lower than in the I/R group.

Discussion
This is the first research to reveal that simvastatin and simvastatin/PEG-b-PBLG50 pretreatment can both weaken intestine injury induced by intestinal I/R. We discovered that intestinal inflammatory reaction is remarkably mitigated after simvastatin and simvastatin/PEG-b-PBLG50 preconditioning. The protective action is partially downregulated with BMP4 and COX-2, manifesting that the underlying mechanisms are associated with either BMP4 and COX-2-dependent or-independent pathways.

The intestinal mucosal injury is a major factor contributing to the pernicious complications of intestinal II/RI.41 It is a well-known phenomenon that ROS-induced lipid peroxidation, proinflammatory and anti-inflammatory imbalance, and disorder of nitroso-redox balance lead to intestinal injury.12,22,45 Previous documents have also demonstrated that powerful oxidative stress starting in the epithelium upon recovery of blood cell circulations is a primary reason of necrosis of the intestinal epithelium on I/R-induced injury.46 In the present study, we demonstrate that simvastatin and simvastatin/PEG-b-PBLG50 pretreatment ameliorate oxidative stress damage, bate inflammatory response, and restore nitroso-redox balance (Figures 5, 6, and 7A).

In the study, we find that on II/RI rats, the protein contents and expression of BMP4 are augmented, and then p38MAPK oxidative stress are activated, leading to upregulation of COX-2 protein levels and expression, where the pathway contributes to augmentation of II/RI. Simvastatin and simvastatin/PEG-b-PBLG50 interestingly reverse the activation of the above pathway (Scheme 1). This also shows that BMP4 can enhance NADPH oxidase to promote NADPH oxidase subtype (including p47phox) expression, resulting in COX-2 expression upregulation through p38MAPK-dependent mechanism in our research. In our study, we found that simvastatin and simvastatin/PEG-b-PBLG50 attenuate BMP4, COX-2, p47phox, p38MAPK, and ROS...
Figure 7 Expression of eNOs (A), p47phox (B), p38MAPK (C), BMP4, and COX-2 (D) in different groups of rats.

Notes: The intestinal tissues of Sham, I/R, Sim, and Sim/P group rats were collected 1 h after reperfusion and the expressions of eNOs, p47phox, p38MAPK, BMP4, and COX-2 measured. Results are expressed as mean ± standard deviation. (A) A significant increase from Sham group is denoted by *P<0.01, an increase from I/R group is denoted by **P<0.01, and a significant increase from I/R group is denoted by ***P<0.01. (B) A significant increase from Sham group is denoted by *P<0.01, a decrease from I/R group is denoted by **P<0.01, and a significant decrease from I/R group is denoted by ***P<0.01. (C) A significant increase from Sham group is denoted by *P<0.01, a decrease from I/R group is denoted by **P<0.01, and a significant decrease from I/R group is denoted by ***P<0.01. (D) A significant increase from Sham group is denoted by *P<0.01, a decrease from I/R group is denoted by **P<0.01, and a significant decrease from I/R group is denoted by ***P<0.01.

Abbreviations: BMP4, bone morphogenetic protein 4; COX-2, cyclooxygenase-2; eNOs, endothelial nitric oxide synthase; I/R, ischemia/reperfusion; p38MAPK, p38 mitogen-activated protein kinase; p47phox, protein 47 kDa phagocyte oxidase; Sim, simvastatin; Sim/P, simvastatin/PEG-b-PBLG50.

Figure 8 Expression of COX-2 (A), BMP4 (B), and p38MAPK (C) in different groups of rats.

Notes: The intestinal tissues of Sham, I/R, Sim, and Sim/P group rats were collected 1 h after reperfusion and the expression of ROS measured. COX-2, BMP4, and p38MAPK expressions in I/R group rats were higher than those in Sham group; COX-2, BMP4, and p38MAPK expressions in Sim group rats were less than those in I/R group; COX-2, BMP4, and p38MAPK expressions in Sim/P group rats were significantly less than those in I/R group.

Abbreviations: BMP4, bone morphogenetic protein 4; COX-2, cyclooxygenase-2; I/R, ischemia/reperfusion; p38MAPK, p38 mitogen-activated protein kinase; Sim, simvastatin; Sim/P, simvastatin/PEG-b-PBLG50.
expression. All of the above experimental results attest that BMP4/ROS/p38MAPK/COX-2 pathway is involved in II/R. These results are in agreement with other documents. To sum up, our present research reveals that simvastatin and simvastatin/PEG-b-PBLG50 preconditioning can provide intestine protection after II/R through downregulating BMP4/COX-2 pathway, whereas simvastatin/PEG-b-PBLG50 significantly improves the effect.

In addition, there are some limitations in our research. In our tests, the HE staining is not measured owing to the limited number of mice. On the other hand, we only found the association between simvastatin and simvastatin/PEG-b-PBLG50 and the BMP4/ROS/p38MAPK/COX-2 pathway. The exact mechanism of how simvastatin and simvastatin/PEG-b-PBLG regulate the above pathway needs to be further explored.

Conclusion
The synthesized PEG-b-PBLG50 can evidently enhance the bioactivity of simvastatin, and the distribution experiment shows that simvastatin/PEG-b-PBLG50 can escape liver phagocytosis to improve the circulation time of simvastatin in vivo. The observational protective effect can be due to the antioxidative stress, anti-inflammatory properties, and the regulation of BMP4/COX-2 pathway by simvastatin/PEG-b-PBLG50 in rats as compared to free simvastatin. Further detailed research is required to probe the underlying mechanisms of simvastatin/PEG-b-PBLG50 on II/RI in rats.

Acknowledgment
This study was financially supported by the Department of Education, Zhejiang Government under Key Research Program.

Author contributions
All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References


